Scientific Concept of the National Cohort (status ... - Nationale Kohorte

More documents

Recommendations

Info

The National Cohort A prospective epidemiologic study resource for health and disease research in Germany Scientific coordination Prof. Dr. Wolfgang Hoffmann University of Greifswald D-17487 Greifswald wolfgang.hoffmann@uni-greifswald.de Prof. Dr. Karl-Heinz Jöckel University Hospital Essen D-45122 Essen k-h.joeckel@uk-essen.de Prof. Dr. Rudolf Kaaks German Cancer Research Center D-69120 Heidelberg r.kaaks@dkfz.de Prof. Dr. Dr. H.-Erich Wichmann Helmholtz-Center Munich D-85764 Neuherberg wichmann@helmholtz-muenchen.de Scientific project management Dr. Karin Halina Greiser, MPH German Cancer Research Center D-69120 Heidelberg h.greiser@dkfz.de PD Dr. Jakob Linseisen Helmholtz-Center Munich D-85764 Neuherberg j.linseisen@helmholtz-muenchen.de Administrative coordination Dr. Susanne Weg-Remers, Mag. rer. pub. German Cancer Research Center D-69120 Heidelberg s.weg-remers@dkfz.de
Page 1: The National Cohort A prospective e
Page 5 and 6: Cluster Berlin-Brandenburg Study ce
Page 7 and 8: Executive Summary V Executive Summa
Page 9 and 10: Full-scale re-assessment after five
Page 11 and 12: IX Executive Summary able risks, by
Page 13 and 14: XI Executive Summary that may requi
Page 15 and 16: Contents XIII Contents A.1 INTrOduC
Page 17 and 18: XV Contents A.3.3.11 Feasibility st
Page 19 and 20: A.5.3 Standardization of sampling m
Page 21 and 22: XIX Contents B.4 Career development
Page 23 and 24: Abbreviations/acronyms Abbreviation
Page 25 and 26: MDOR Minimally detectable odds rati
Page 27 and 28: A SCiENTifiC CoNCEpT A.1 introducti
Page 29 and 30: 3 A.1 Introduction and overview The
Page 31 and 32: Biobanking Calendar year Study year
Page 33 and 34: � Cardiovascular diseases � Dia
Page 35 and 36: 9 A.1 Introduction and overview �
Page 37 and 38: 11 A.1 Introduction and overview
Page 39 and 40: 13 A.1 Introduction and overview
Page 41 and 42: 15 A.1 Introduction and overview In
Page 43 and 44: 17 A.1 Introduction and overview wh
Page 45 and 46: A.1.8 Preparatory work for the Nati
Page 47 and 48: A.2 Scientific background and ratio
Page 49 and 50: Major diseases: � CVD � Diabete
Page 51 and 52: A.2 Scientific background and ratio
Page 53 and 54:
A.2 Scientific background and ratio
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
A.3 Study design A.3.1 Population s
Page 83 and 84:
57 A.3 Study design of Germany, plu
Page 85 and 86:
Unemployment rate $ Population move
Page 87 and 88:
A.3.1.2 Population sampling Samplin
Page 89 and 90:
Important aspects for enhancing ind
Page 91 and 92:
65 A.3 Study design detailed study
Page 93 and 94:
67 A.3 Study design The respective
Page 95 and 96:
Table 3.4: Modules of the core inte
Page 97 and 98:
Family history 71 A.3 Study design
Page 99 and 100:
73 A.3 Study design For the Nationa
Page 101 and 102:
Diet * Modules Simplified 24-h diet
Page 103 and 104:
77 A.3 Study design fore. It includ
Page 105 and 106:
Instruments: 79 A.3 Study design On
Page 107 and 108:
Physical activity 81 A.3 Study desi
Page 109 and 110:
Instruments: 83 A.3 Study design In
Page 111 and 112:
85 A.3 Study design sources. Aspect
Page 113 and 114:
Anthropometry: Instruments Level 1
Page 115 and 116:
89 A.3 Study design The device will
Page 117 and 118:
91 A.3 Study design Several new dev
Page 119 and 120:
93 A.3 Study design fluency (e.g.,
Page 121 and 122:
95 A.3 Study design group (dental e
Page 123 and 124:
97 A.3 Study design 200,000 America
Page 125 and 126:
99 A.3 Study design By using triaxi
Page 127 and 128:
101 A.3 Study design Table 3.8: Fea
Page 129 and 130:
Project title Main objectives Signi
Page 131 and 132:
105 A.3 Study design cal cerebrovas
Page 133 and 134:
107 A.3 Study design dictive value
Page 135 and 136:
figure 3.2: Interaction between stu
Page 137 and 138:
Sequence Duration (min) Phenotypic
Page 139 and 140:
113 A.3 Study design and from there
Page 141 and 142:
115 A.3 Study design sample drawing
Page 143 and 144:
Urine 117 A.3 Study design Urine pr
Page 145 and 146:
Primary material Volume Processed m
Page 147 and 148:
121 A.3 Study design � manual wor
Page 149 and 150:
Retrieval of biomaterials 123 A.3 S
Page 151 and 152:
125 A.3 Study design � Sustainabi
Page 153 and 154:
127 A.3 Study design A.3.6.2 Assess
Page 155 and 156:
A.3.7.2 recontacting and tracking o
Page 157 and 158:
Table 3.15: Assessment of incident
Page 159 and 160:
� CHD endpoint committee � Canc
Page 161 and 162:
135 A.3 Study design to standard cl
Page 163 and 164:
137 A.3 Study design A.3.8.5 Experi
Page 165 and 166:
139 A.3 Study design comparison to
Page 167 and 168:
CONSTANCES France The National Coho
Page 169 and 170:
A.4 integrated data management A.4.
Page 171 and 172:
A.4.2 Organizational model 145 A.4
Page 173 and 174:
figure 4.3: Organizational units an
Page 175 and 176:
149 A.4 Integrated Data Management
Page 177 and 178:
A.4.2.5 data transfer and project d
Page 179 and 180:
153 A.4 Integrated Data Management
Page 181 and 182:
A.5 Methods for quality assurance a
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
A.6 Planned statistical analyses an
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Table 6.5: Expected counts of incid
Page 207 and 208:
Page 209 and 210:
1000 0 1.2 1.3 1.4 1.5 1.6 1.7 1.8
Page 211 and 212:
2000 1000 0 0.05 0.1 0.15A.6 Planne
Page 213 and 214:
Page 215 and 216:
Table 6.7: Number of cases and cont
Page 217 and 218:
A.7 Ethical aspects 191 A.7 Ethical
Page 219 and 220:
193 A.7 Ethical aspects The consent
Page 221 and 222:
Examination Risks Contraindication
Page 223 and 224:
197 A.7 Ethical aspects health prot
Page 225 and 226:
Use of secondary data 199 A.7 Ethic
Page 227 and 228:
201 A.7 Ethical aspects It will tak
Page 229 and 230:
Control of data protection 203 A.7
Page 231 and 232:
205 A.7 Ethical aspects To reach th
Page 233 and 234:
C.1 Description of the study center
Page 235 and 236:
Institution Town Principal investig
Page 237 and 238:
229 C.1 Annex: Description of the s
Page 239 and 240:
Page 241 and 242:
Table 1: Overview of participating
Page 243 and 244:
Study center Freiburg Table 6: Over
Page 245 and 246:
Study center Saarbruecken 237 C.1 A
Page 247 and 248:
C.1.3 Cluster North rhine-westphali
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
C.1.4 Cluster Saxony/Saxony-Anhalt
Page 255 and 256:
Page 257 and 258:
C.1.5 Cluster Berlin-Brandenburg 24
Page 259 and 260:
Page 261 and 262:
Description of the study center Ber
Page 263 and 264:
Page 265 and 266:
Institution Town Associated scienti
Page 267 and 268:
Table 1: Overview of participating
Page 269 and 270:
Page 271 and 272:
C.1.7 Cluster Schleswig-holstein 26
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
C.1.8.2 Study center 269 C.1 Annex:
Page 279 and 280:
Page 281 and 282:
C.2 Annex: Methods for Statistical
Page 283 and 284:
Page 285 and 286:
Table S6.3: Minimum detectable odds
Page 287 and 288:
Table S6.6a: Minimum detectable odd
Page 289 and 290:
Table S6.7a: Minimum detectable odd
Page 291 and 292:
Page 293 and 294:
Table S.6.9: Statistical power for
Page 295 and 296:
C.3 References 287 References 1. RK
Page 297 and 298:
289 References 32. Burton, P., et a
Page 299 and 300:
291 References 67. Hecht, J.L. and
Page 301 and 302:
293 References 102. Fairbanks, V.,
Page 303 and 304:
295 References 138. Wheeler, J.G.,
Page 305 and 306:
297 References 172. Gerrits, E.G.,
Page 307 and 308:
299 References 207. ATS, ATS Worksh
Page 309 and 310:
301 References 242. Bonora, E., et
Page 311 and 312:
303 References 277. Koster, A., et
Page 313 and 314:
305 References 311. Weyers, S., et
Page 315 and 316:
307 References 344. Loucks, E.B., e
Page 317 and 318:
309 References 378. Sauerbrei, A.,
Page 319 and 320:
311 References 413. Netterstrøm, B
Page 321 and 322:
313 References 447. Lakshman, R., e
Page 323 and 324:
315 References 478. Deacon, B.J., e
Page 325 and 326:
317 References 510. Kristensen, T.S
Page 327 and 328:
319 References 543. Holle, R., et a
Page 329 and 330:
321 References 576. Criqui, M.H., e
Page 331 and 332:
323 References 605. Kaplan, G.A., e
Page 333 and 334:
325 References 641. Samaras, T.T.,
Page 335 and 336:
327 References 675. Bellace, J.V.,
Page 337 and 338:
329 References 708. Wilson, G.J. an
Page 339 and 340:
331 References 743. Boshuizen, H.C.
Page 341 and 342:
333 References 773. Ostrowski, C. a
Page 343 and 344:
335 References 807. Gail, M.H., Est
show all

Scientific Concept of the National Cohort (status ... - Nationale Kohorte

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?